Guidelines for Adult Immunisation

Special Groups

Human Immunodeficiency Virus (HIV)

Table 21.5 Immunisation for HIV Patients

table 21.5


  1. Benson, C. A., Andersen, J. W., Macatangay, B. J. C., Mailliard, R. B., Rinaldo, C. R., Read, S., Bozzolo, D. R., Purdue, L., Jennings, C., Keefer, M. C., Glesby, M., Tebas, P., Russell, A. F., Martin, J., Annunziato, P., Popmihajlov, Z., & Lennox, J. L. (2018). Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 67(11), 1712–1719.
  2. Pacanowski, J., Lacombe, K., Campa, P., Dabrowska, M., Poveda, J.-D., Meynard, J.-L., Poirot, J.-L., Fonquernie, L., & Girard, P.-M. (2012). Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999), 59(4), 360–367.